



STATE OF OKLAHOMA
OKLAHOMA HEALTH CARE AUTHORITY

OHCA 2016-21

July 28, 2016

RE: Prior Authorization of Molecular Pathology CPT Codes Related to Hereditary Cancer Susceptibility Testing – Effective September 1, 2016

Dear Provider,

Beginning September 1, 2016, the Oklahoma Health Care Authority (OHCA) will require prior authorization (PA) for the following molecular pathology CPT codes related to hereditary cancer susceptibility testing:

- 81162: BRCA1, BRCA2 gene analysis; full sequence analysis and full duplication/deletion analysis
- 81201: APC gene analysis; full gene sequence
- 81203: APC gene analysis; duplication/deletion variants
- 81211: BRCA1, BRCA2 gene analysis; full sequence analysis and common duplication/deletion variants
- 81213: BRCA1, BRCA2 gene analysis; uncommon duplication/deletion variants
- 81214: BRCA1 gene analysis; full sequence analysis and common duplication/deletion variants
- 81216: BRCA2 gene analysis; full sequence analysis
- 81292: MLH1 gene analysis; full sequence analysis
- 81294: MLH1 gene analysis; duplication/deletion variants
- 81295: MSH2 gene analysis; full sequence analysis
- 81297: MSH2 gene analysis; duplication/deletion variants
- 81298: MSH6 gene analysis; full sequence analysis
- 81300: MSH6 gene analysis; duplication/deletion variants
- 81317: PMS2 gene analysis; full sequence analysis
- 81319: PMS2 gene analysis; duplication/deletion variants
- 81321: PTEN gene analysis; full sequence analysis
- 81323: PTEN gene analysis; duplication/deletion variant

As a reminder, the following related codes already require PA:

- 81432: Hereditary breast cancer-related disorders; genomic sequence analysis panel
- 81433: Hereditary breast cancer-related disorders; duplication/deletion analysis panel
- 81435: Hereditary colon cancer disorders; genomic sequence analysis panel
- 81436: Hereditary colon cancer disorders; duplication/deletion analysis panel

OHCA may consider the use of the tests described above to be medically necessary for individuals that meet the relevant NCCN guidelines based on their personal or family history of cancer. Please note that when testing for more than one gene in a single test, OHCA considers it appropriate to bill the single code reflective of the test being performed. Billing multiple codes when numerous genes are examined as part of a single test is not considered appropriate.

OHCA requires the submission of all of the following documents for prior authorization review:

- HCA-13A Prior Authorization Form Cover Sheet
- HCA-12A Prior Authorization Form
- Objective clinical records supporting the medical necessity of the request

JOEL NICO GOMEZ
CHIEF EXECUTIVE OFFICER



MARY FALLIN
GOVERNOR

STATE OF OKLAHOMA
OKLAHOMA HEALTH CARE AUTHORITY

If you have any questions regarding PA forms and documentation, please contact OHCA's Medical Authorization Unit at 1-800-522-0114. If you have questions regarding OHCA's coverage of molecular pathology CPT codes, please contact Alison Martinez, Ph.D. at alison.martinez@okhca.org.

Thank you for the services you provide to our SoonerCare and Insure Oklahoma members.

Sincerely,

A handwritten signature in cursive script that reads "Rebecca Pasternik-Ikard".

Rebecca Pasternik-Ikard
State Medicaid Director